OncoTherapy Science, Inc.
4564
Rank in Stocks
#23264
OncoTherapy Science, Inc. engages in research and development of anti-body... OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.
Share Price
$0.10760413
Last synced: 2026-11-10
Market Cap
$43.93M
Change (1 day)
6.25%
Change (1 year)
-30.63%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade OncoTherapy Science, Inc. (4564)
Category
Healthcare
EPS for OncoTherapy Science, Inc. (4564)
EPS as of June 2026 TTM: $-0.01
According to OncoTherapy Science, Inc.'s latest financial reports, its current EPS (TTM) is $-0.01. At the end of 2025 the company had an EPS of $-0.02, an increase over its 2024 EPS of $-0.04.
EPS history for OncoTherapy Science, Inc. from 2005 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.01 | -25.50% |
| 2025 | $-0.02 | -48.00% |
| 2024 | $-0.04 | -8.68% |
| 2023 | $-0.04 | -61.14% |
| 2022 | $-0.11 | 40.88% |
| 2021 | $-0.08 | -37.35% |
| 2020 | $-0.13 | -28.78% |
| 2019 | $-0.18 | -1.75% |
| 2018 | $-0.18 | -0.44% |
| 2017 | $-0.18 | 8.72% |
| 2016 | $-0.17 | 122.43% |
| 2015 | $-0.08 | -72.28% |
| 2014 | $-0.27 | 151.75% |
| 2013 | $-0.11 | -229.59% |
| 2012 | $0.08 | 26.59% |
| 2011 | $0.07 | 22.82% |
| 2010 | $0.05 | 259.33% |
| 2009 | $0.02 | -172.82% |
| 2008 | $-0.02 | -82.04% |
| 2007 | $-0.11 | 148.27% |
| 2006 | $-0.05 | -2,817.65% |
| 2005 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -105,200.67% |
US
|
|
| $-7.07 | 47,349.66% |
US
|
|
| $-5.29 | 35,403.36% |
AU
|
|
| $12.88 | -86,543.62% |
BE
|
|
| $21.56 | -144,797.99% |
NL
|
Questions about OncoTherapy Science, Inc.'s earnings per share (EPS)
What is OncoTherapy Science, Inc.'s earnings per share (EPS)?
OncoTherapy Science, Inc.'s earnings per share (EPS) over the last twelve months is $-0.01, as of Jun 2026.
What was OncoTherapy Science, Inc.'s earnings per share (EPS) in 2025?
In 2025, OncoTherapy Science, Inc.'s earnings per share (EPS) was $-0.02, compared with $-0.04 in 2024.
How has OncoTherapy Science, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, OncoTherapy Science, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.02) and lowest in 2020 ($-0.13).
How does OncoTherapy Science, Inc.'s earnings per share (EPS) compare with similar companies?
OncoTherapy Science, Inc.'s earnings per share (EPS) ($-0.01) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.